Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

IMRX

Immuneering Corp

Jan 13 • 04:00PM ET

4.14

-0.08 -2.01 %

Healthcare • Biotechnology • USA • NASD

Jan 08, 9:31 AMPhase 2a pancreatic cancer trial data release sparked 28% plunge due to investor concerns over Phase 3 execution risks.

Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP

| Held by: VTI XBI VXF IBB IWC LABU AVSC DFAC IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	24.39%	Shs Outstand	63.48M	Perf Week	-38.47%
Market Cap	267.00M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	0.14%	Shs Float	48.82M	Perf Month	-33.31%
Enterprise Value	43.36M	PEG	-	EPS next Q	-0.31	Inst Own	41.88%	Short Float	22.38%	Perf Quarter	-32.65%
Income	-62.50M	P/S	-	EPS this Y	30.54%	Inst Trans	73.19%	Short Ratio	6.32	Perf Half Y	-1.08%
Sales	0.00M	P/B	1.15	EPS next Y	-3.15%	ROA	-40.37%	Short Interest	10.92M	Perf YTD	-37.16%
Book/sh	3.59	P/C	1.17	EPS next 5Y	8.87%	ROE	-43.75%	52W High	10.08 -58.98%	Perf Year	99.76%
Cash/sh	3.52	P/FCF	-	EPS past 3/5Y	-16.91% -46.45%	ROIC	-26.99%	52W Low	1.10 275.91%	Perf 3Y	4.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	18.60% 9.78%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.32%	Oper. Margin	-	ATR (14)	0.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.00	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.40	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.00	EPS Q/Q	22.89%	SMA20	-31.18%	Beta	0.44	Target Price	16.83
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-36.07%	Rel Volume	1.49	Prev Close	4.22
Employees	66	LT Debt/Eq	0.02	Earnings	Nov 12 AMC	SMA200	-7.96%	Avg Volume	1.73M	Price	4.14
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.14% -	Trades		Volume	2,567,703	Change	-2.01%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Initiated	Leerink Partners	Outperform	$15
Dec-13-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Jan-08-26 09:28AM	Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (Benzinga) -43.22%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 07:03PM	Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 (MarketBeat) +23.96%
04:00PM	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Dec-29-25 12:00PM	All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy (Zacks)
08:00AM	Loading…
Dec-23-25 08:00AM	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 (GlobeNewswire) +8.12%
Dec-17-25 04:05PM	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA (GlobeNewswire)
Dec-16-25 08:00AM	Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Nov-26-25 12:00PM	Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? (Zacks)
Nov-25-25 08:00AM	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 (GlobeNewswire)
09:33AM	Loading…
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly) +7.18%
Sep-30-25 11:42AM	Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) (Insider Monkey)
Sep-26-25 04:01PM	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 (GlobeNewswire) -16.46%
Sep-25-25 12:08AM	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi (GlobeNewswire) -13.33%
Sep-24-25 04:05PM	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi (GlobeNewswire) +7.45%
04:01PM	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Sep-16-25 07:00AM	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board (GlobeNewswire) +5.73%
Sep-10-25 07:00AM	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 (GlobeNewswire) +15.46%
Aug-26-25 04:05PM	Immuneering Announces Closing of $25 Million Private Placement (GlobeNewswire) -12.33%
11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
Aug-25-25 08:00AM	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib (GlobeNewswire) +21.68%
Aug-21-25 08:00AM	Immuneering Announces $25 Million Private Placement (GlobeNewswire) +34.99%
Aug-13-25 04:05PM	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.59%
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 08:00AM	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib (GlobeNewswire) +11.25%
04:00AM	Loading…
Jul-08-25 04:00AM	The MEK effect on cancer a slow and steady approach to drug resistance (Pharma Voice)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -7.58%
Jun-17-25 06:00AM	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients (GlobeNewswire) -23.21%
Jun-16-25 08:00AM	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 (GlobeNewswire) +24.74%
May-29-25 08:00AM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.83%
May-05-25 04:05PM	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-25 08:00AM	Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	Immuneering Corporation Announces Grant of Inducement Award (GlobeNewswire) +9.09%
Mar-20-25 04:05PM	Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:12AM	Immuneering names Igor Matushansky as chief medical officer (SeekingAlpha)
07:00AM	Immuneering Names Dr. Igor Matushansky as Chief Medical Officer (GlobeNewswire)
Feb-06-25 07:00AM	Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) (GlobeNewswire)
Feb-03-25 04:05PM	Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer (GlobeNewswire)
Jan-07-25 09:28AM	Why Is Immuneering Stock Trading Higher On Tuesday? (Benzinga)
07:00AM	Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +10.00%
Dec-19-24 08:00AM	Immuneering Launches Pancreatic Cancer Advisory Board (GlobeNewswire) +13.58%
Dec-17-24 08:00AM	Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -17.01%
Dec-12-24 08:00AM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma (GlobeNewswire) -7.94%
Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +25.45%
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feinberg Peter	Director	Oct 03 '25	Buy	6.67	7,500	50,025	156,766	Oct 07 08:56 AM
Morales Mallory	Chief Accounting Officer	Oct 01 '25	Buy	6.39	300	1,917	27,533	Oct 02 09:02 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Oct 01 '25	Buy	6.38	800	5,103	23,344	Oct 02 08:57 AM
Bookman Michael	CHIEF LEGAL OFFICER, SECRETARY	Oct 01 '25	Buy	6.83	1,020	6,966	4,870	Oct 02 08:52 AM
Feinberg Peter	Director	Sep 30 '25	Buy	7.03	7,500	52,730	149,266	Oct 01 08:59 AM
Feinberg Peter	Director	Sep 29 '25	Buy	7.18	5,000	35,900	141,766	Sep 30 09:00 AM
BERMAN ANN E	Director	Sep 23 '25	Proposed Sale	9.72	14,000	136,080		Sep 23 08:48 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.62	3,000	10,874	3,000	Jul 07 08:59 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.60	2,500	8,989	2,500	Jul 07 08:59 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jul 02 '25	Buy	3.57	700	2,499	10,729	Jul 07 08:52 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 02 '25	Buy	3.53	7,015	24,792	2,312,852	Jul 03 09:12 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 01 '25	Buy	3.38	2,985	10,087	2,305,837	Jul 03 09:12 AM
Schall Thomas J.	Director	Jun 27 '25	Buy	3.66	9,500	34,788	52,885	Jun 30 09:09 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Buy	2.70	7,415	20,020	353,311	Jun 24 09:01 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 23 '25	Buy	2.43	6,007	14,596	359,318	Jun 24 09:01 AM
Brakewood Harold Eugene	Chief Business Officer	Jun 20 '25	Buy	2.53	1,900	4,804	5,800	Jun 24 08:52 AM
Feinberg Peter	Director	Jun 18 '25	Buy	2.53	25,000	63,188	136,766	Jun 23 09:09 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jun 18 '25	Buy	2.39	21,000	50,144	2,302,852	Jun 20 09:09 AM
Schall Thomas J.	Director	Jun 17 '25	Buy	2.21	40,485	89,278	43,385	Jun 18 09:11 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRX

Immuneering Corp

Upgrade your FINVIZ experience